Northern Trust Corp Revance Therapeutics, Inc. Transaction History

Northern Trust Corp

$600 Billion
Q3 2024

A detailed history of Northern Trust Corp transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 964,795 shares of RVNC stock, worth $2.48 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

964,795

Previous 866,186 11.38%

Holding current value

$2.48 Million

Previous $2.23 Million 11.37%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$2.57 - $2.57 $253,425 - $253,425	98,609 Added 11.38%	964,795 $2.48 Million
Q2 2024 Aug 14, 2024	BUY	$2.34 - $4.73 $2,239 - $4,526	957 Added 0.11%	866,186 $2.23 Million
Q1 2024 May 14, 2024	SELL	$4.65 - $9.31 $103,727 - $207,678	-22,307 Reduced 2.51%	865,229 $4.26 Million
Q4 2023 Feb 13, 2024	BUY	$5.81 - $11.2 $285,735 - $550,816	49,180 Added 5.87%	887,536 $7.8 Million
Q3 2023 Nov 13, 2023	BUY	$11.47 - $25.07 $98,435 - $215,150	8,582 Added 1.03%	838,356 $9.62 Million
Q2 2023 Aug 11, 2023	BUY	$24.7 - $37.61 $584,747 - $890,379	23,674 Added 2.94%	829,774 $21 Million
Q1 2023 May 15, 2023	BUY	$18.36 - $35.27 $232,566 - $446,765	12,667 Added 1.6%	806,100 $26 Million
Q4 2022 Feb 13, 2023	BUY	$18.32 - $30.66 $1.43 Million - $2.38 Million	77,784 Added 10.87%	793,433 $14.6 Million
Q3 2022 Nov 14, 2022	BUY	$14.33 - $28.47 $535,211 - $1.06 Million	37,349 Added 5.51%	715,649 $19.3 Million
Q2 2022 Aug 12, 2022	SELL	$11.52 - $20.4 $326,200 - $577,646	-28,316 Reduced 4.01%	678,300 $9.37 Million
Q1 2022 May 13, 2022	SELL	$12.36 - $20.31 $295,910 - $486,241	-23,941 Reduced 3.28%	706,616 $13.8 Million
Q4 2021 Feb 08, 2022	SELL	$12.46 - $27.87 $93,761 - $209,721	-7,525 Reduced 1.02%	730,557 $11.9 Million
Q3 2021 Nov 15, 2021	SELL	$25.78 - $33.21 $354,990 - $457,301	-13,770 Reduced 1.83%	738,082 $20.6 Million
Q2 2021 Aug 13, 2021	BUY	$26.8 - $31.84 $803,705 - $954,849	29,989 Added 4.15%	751,852 $22.3 Million
Q1 2021 May 12, 2021	SELL	$24.03 - $29.97 $1 Million - $1.25 Million	-41,761 Reduced 5.47%	721,863 $20.2 Million
Q4 2020 Feb 11, 2021	SELL	$23.41 - $28.34 $545,546 - $660,435	-23,304 Reduced 2.96%	763,624 $21.6 Million
Q3 2020 Nov 16, 2020	BUY	$23.23 - $34.3 $1.13 Million - $1.66 Million	48,463 Added 6.56%	786,928 $19.8 Million
Q2 2020 Aug 14, 2020	BUY	$12.6 - $26.55 $971,119 - $2.05 Million	77,073 Added 11.65%	738,465 $18 Million
Q1 2020 May 14, 2020	BUY	$12.46 - $27.81 $921,641 - $2.06 Million	73,968 Added 12.59%	661,392 $9.79 Million
Q4 2019 Feb 14, 2020	BUY	$11.66 - $20.15 $285,600 - $493,554	24,494 Added 4.35%	587,424 $9.53 Million
Q3 2019 Nov 13, 2019	BUY	$10.22 - $14.5 $587,496 - $833,532	57,485 Added 11.37%	562,930 $7.32 Million
Q2 2019 Aug 13, 2019	BUY	$10.67 - $15.49 $69,472 - $100,855	6,511 Added 1.3%	505,445 $6.56 Million
Q1 2019 May 13, 2019	BUY	$15.4 - $20.39 $1.09 Million - $1.44 Million	70,584 Added 16.48%	498,934 $7.86 Million
Q4 2018 Feb 12, 2019	SELL	$18.06 - $24.96 $189,973 - $262,554	-10,519 Reduced 2.4%	428,350 $8.62 Million
Q3 2018 Nov 14, 2018	BUY	$23.55 - $30.1 $541,956 - $692,691	23,013 Added 5.53%	438,869 $10.9 Million
Q2 2018 Sep 18, 2018	SELL	$27.45 - $33.35 $64,836 - $78,772	-2,362 Reduced 0.56%	415,856 $11.4 Million
Q2 2018 Aug 14, 2018	BUY	$27.45 - $33.35 $2.16 Million - $2.63 Million	78,768 Added 23.2%	418,218 $11.5 Million
Q1 2018 May 09, 2018	BUY	$29.15 - $37.4 $1.11 Million - $1.42 Million	38,045 Added 12.62%	339,450 $10.5 Million
Q4 2017 Feb 14, 2018	BUY	$24.55 - $36.3 $256,670 - $379,516	10,455 Added 3.59%	301,405 $10.8 Million
Q3 2017 Nov 13, 2017	BUY	$22.55 - $28.1 $6.56 Million - $8.18 Million	290,950	290,950 $8.02 Million

Others Institutions Holding RVNC

# of Institutions

234

Shares Held

82.8M

Call Options Held

680K

Put Options Held

896K

View Full List

About Revance Therapeutics, Inc.

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

More about RVNC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Account

Northern Trust Corp Revance Therapeutics, Inc. Transaction History